Mergers and Acquisitions

Baxter Completes Its Acquisition Of ASTA Medica Oncology

Published in Cancer Weekly, November 27th, 2001

Baxter International, Inc., (BAX) has completed its acquisition of ASTA Medica Onkologie GmbH & Co KG, a subsidiary of Dusseldorf-based Degussa, AG for approximately EURO 525 million [US$470 million].

ASTA Medica Oncology develops, produces, and markets oncology products worldwide. ASTA Medica Oncology's pro forma sales, primarily of chemotherapy agents, totaled approximately US$130 million in 2000. The company's leading products include cyclophosphamide (marketed as Endoxan), ifosfamide (marketed as Holoxan and as Ifex in the United States), and mesna (marketed as Uromitexan and as Mesnex in the United States).

"We believe our combined strengths...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-11-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry